Psychedelics are a class of psychoactive substances that alter perception, mood, and cognition, and have been investigated for their therapeutic potential, particularly in mental health treatment. Within the effective altruism (EA) community, psychedelics have gained attention as a potentially high-impact intervention due to their promising results in treating mental health conditions, their possible role in improving human well-being, and their capacity to induce perspective-shifting experiences that may influence long-term altruistic behavior.
Psychedelic-assisted mental health treatments involve the use of substances such as psilocybin or MDMA, often combined with psychotherapy. Clinical studies have demonstrated their effectiveness in treating conditions such as major depressive disorder (MDD), post-traumatic stress disorder (PTSD), anxiety, and addiction. These treatments typically include preparatory sessions, supervised psychedelic experiences, and integration therapy. Results have shown large effect sizes and long-lasting symptom relief, particularly for treatment-resistant cases.
Key institutions leading this research include:
Proponents argue that psychedelics are compelling as an EA cause area for both short-termist and long-termist frameworks:
Funding psychedelic research has historically been neglected due to stigma and regulatory barriers. However, a small group of private donors (e.g. Tim Ferriss, Open Philanthropy, Founders Pledge) has seeded a growing body of clinical and translational work. Notable philanthropic initiatives include:
Despite enthusiasm, some within EA remain skeptical. A prize-funded forum thread solicited arguments against psychedelics as an EA cause area, aiming to surface overlooked downsides. Key concerns include:
Beyond depression and PTSD, psychedelics are being explored for: